Bicycle Therapeutics PLC (BCYC)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.
Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.
In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications.
It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets.
Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
|IPO Date||May 23, 2019|
Cambridge, Cambridgeshire CB22 3AT
|Phone||44 1223 261 503|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Kevin Lee M.B.A., Ph.D.||Chief Executive Officer and Executive Director|
|Lee H. Kalowski M.B.A., MBA||President and Chief Financial Officer|
|Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE||Co-Founder, Non-Executive Director and Member of Scientific Advisory Board|
|Dr. Michael Skynner B.sc. Ph.d., Ph.D.||Chief Technology Officer|
|Dr. Christian Heinis||Scientific Founder|
|Alistair Milnes||Chief Operating Officer|
|Dr. Nicholas Keen Ph.D.||Chief Scientific Officer|
|David E. Borah CFA||Vice President of Capital Markets and Investor Relations|
|Zafar Qadir||General Counsel|
|Dr. Gillian Langford||Head of Clinical and Project Management|
Latest SEC Filings
|May 5, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 5, 2022||8-K||Current report|
|May 2, 2022||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Apr 29, 2022||DEF 14A||Other definitive proxy statements|
|Apr 15, 2022||PRE 14A||Other preliminary proxy statements|
|Apr 12, 2022||8-K||Current report|
|Mar 29, 2022||4||Statement of changes in beneficial ownership of securities|
|Mar 29, 2022||3/A||Initial statement of beneficial ownership of securities|
|Mar 14, 2022||SC 13D/A||General statement of acquisition of beneficial ownership|
|Mar 1, 2022||S-8||Securities to be offered to employees in employee benefit plans|
|View All SEC Filings|